Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OK Biotech CoTPE:4155 -0.63%65 ROC (Joel Greenblatt) % is 10.60% as of Dec. 2025, which is 35% below its 10-year median of 16.26. GuruFocus rates TPE:4155 with a GF Score™ of 65/100 and a GF Value™ of NT$27.23 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 838 Medical Devices & Instruments companies, OK Biotech Co ranks better than 50.24% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. OK Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 10.60%.
The historical rank and industry rank for OK Biotech Co's ROC (Joel Greenblatt) % or its related term are showing as below:
TPE:4155'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 1.22 Med: 16.26 Max: 28.65
Current: 4.35
During the past 13 years, OK Biotech Co's highest ROC (Joel Greenblatt) % was 28.65%. The lowest was 1.22%. And the median was 16.26%.
TPE:4155's ROC (Joel Greenblatt) % is ranked better than 50.24% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs TPE:4155: 4.35
OK Biotech Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -21.70% per year.
OK Biotech Co (TPE:4155) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
OK Biotech Co ROC (Joel Greenblatt) % Related Terms
OK Biotech Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for OK Biotech Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4155 vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, OK Biotech Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OK Biotech Co ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OK Biotech Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where OK Biotech Co's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 10.60% mean?
OK Biotech Co (TPE:4155) has a ROC (Joel Greenblatt) % of 10.60% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on OK Biotech Co and its competitors. This is 35% below median its historical median of 16.26. Over the past decade, OK Biotech Co's ROC (Joel Greenblatt) % has ranged from 1.22 to 28.65. According to the industry distribution chart, OK Biotech Co ranks #417 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 49.8%.
Is OK Biotech Co's ROC (Joel Greenblatt) % too high?
OK Biotech Co's current ROC (Joel Greenblatt) % of 10.60% is 35% below median its 10-year median of 16.26. Over the past 10 years, this metric has ranged from a low of 1.22 to a high of 28.65. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. OK Biotech Co's value of 10.60% is 155.7% above this industry median. Based on the distribution chart, OK Biotech Co ranks #417 out of 838 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, OK Biotech Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OK Biotech Co's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OK Biotech Co ranks #417 out of 838 companies for ROC (Joel Greenblatt) %. This puts OK Biotech Co in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.15. OK Biotech Co's value of 10.60% is 155.7% above this benchmark. Historically, OK Biotech Co's own ROC (Joel Greenblatt) % has ranged from 1.22 to 28.65 over the past decade. While the company's 10-year median is 16.26 vs. the industry median of 4.15, OK Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OK Biotech Co's current ROC (Joel Greenblatt) % of 10.60% is 155.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on OK Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OK Biotech Co's current ROC (Joel Greenblatt) % is 10.60%, which is 35% below median its own 10-year median of 16.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OK Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, OK Biotech Co (TPE:4155) is currently considered Possible Value Trap. The stock's GF Value™ is NT$27.23, compared to a current price of NT$15.80 — trading 42% below its estimated fair value. The current ROC (Joel Greenblatt) % is 10.60%, which is 35% below median its 10-year median of 16.26 and 155.7% above the Medical Devices & Instruments industry median of 4.15. OK Biotech Co's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For OK Biotech Co (TPE:4155), the current ROC (Joel Greenblatt) % is 10.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OK Biotech Co (TPE:4155) Overvalued in 2026?
Based on GuruFocus' analysis, OK Biotech Co stock appears to be undervalued.
The current stock price of NT$15.80 is trading 42% below its estimated GF Value™ of NT$27.23.
GuruFocus considers OK Biotech Co to be Possible Value Trap.
Key valuation signals for TPE:4155:
ROC (Joel Greenblatt) %: 10.60% (35% below median its 10-year median of 16.26)
GF Value™: NT$27.23 vs. price of NT$15.80 (42% below fair value)
Industry Position: 155.7% above the Medical Devices & Instruments median (#417 of 838)
No single metric tells the full story. See the TPE:4155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OK Biotech Co Ltd is mainly engaged in the manufacturing, wholesale, and retail of electronic materials and medical equipment. Its product portfolio comprises blood glucose monitoring systems, OTC hearing aids, multi-frequency therapy devices, and others. Geographically, the company generates the majority of its revenue from America, and the rest from Asia (excluding Taiwan), Africa, Europe, and Taiwan.
65GF Score
Get the complete analysis for TPE:4155
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4155 has been successfully added to your 
